In a move aimed at accelerating its path to commercialization, Tevogen Bio, a clinical-stage immunotherapy biotech company, has appointed health care industry veteran David E. Banko as global head of government affairs and patient access.
The biotech firm, which specializes in AI-driven immunotherapy drug discovery, is positioning itself for growth in key therapeutic areas, including oncology, virology, neurology and rheumatology. Banko’s expertise in market access strategy, health policy and payer engagement will be critical as Tevogen advances its pipeline toward regulatory approval and market entry.
Tevogen Bio, headquartered in Iselin, has been gaining attention for its innovative approach to immunotherapy, aiming to deliver accessible and cost-effective treatment options. The company’s latest leadership hire reflects a broader industry trend — biotech firms are increasingly prioritizing market access strategies earlier in the drug development process to ensure commercial viability.
“David’s appointment marks an important milestone in Tevogen’s transition toward commercialization readiness,” said Dr. Ryan Saadi, CEO and founder of Tevogen Bio. “Scientific excellence alone isn’t enough in today’s health care environment. We need to define clear value propositions for patients, providers, payers and policymakers. David’s experience in market access and health policy will be instrumental in making our therapies more accessible and ensuring long-term success.”
Banko brings more than 30 years of experience across the pharmaceutical, medical device, diagnostics and hospital finance sectors. His previous roles at Cordis Corp., a former Johnson & Johnson company, and B. Braun Medical Inc. have equipped him with a deep understanding of reimbursement pathways, health technology assessments and payer negotiations — critical components in the commercialization of breakthrough medical innovations.
His work has been instrumental in securing Medicare national coverage policies, optimizing global pricing strategies and advancing the adoption of emerging technologies among health care providers. At Tevogen, Banko will focus on shaping policy engagement with both government and private payers while ensuring the company’s therapies are positioned for successful provider reimbursement upon launch.
New Jersey has long been a hub for pharmaceutical and biotechnology companies, housing some of the biggest names in the industry. Tevogen Bio’s continued investment in leadership and commercialization strategies underscores the state’s role as a key player in life sciences innovation. With a growing emphasis on personalized medicine and advanced therapies, companies like Tevogen are poised to shape the next generation of health care solutions.
As the company advances its product pipeline, the appointment of Banko signals a shift from pure research and development toward a more commercially focused strategy. For New Jersey’s business community, Tevogen’s trajectory highlights the evolving landscape of biotech and the economic potential of homegrown innovation.
With Banko at the helm of government affairs and patient access, Tevogen Bio aims to navigate the complexities of the health care market, ensuring that its cutting-edge therapies reach the patients who need them most. The move also serves as a reminder that beyond scientific breakthroughs, the business of biotech hinges on strategic execution and market access readiness.
